Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 2 and 1 bp insertion in exon 2,
Disease:Adenocarcinoma
Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-IER2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The immediate early response gene 2 (IER2) also known as ETR101 is a protein with a molecular mass of approximately 30 kDa. Researchers often find IER2 expressed across various tissues including the heart kidney and brain. Being an immediate early gene IER2 rapidly responds to growth factors stress and other stimuli. Its function does not require de novo protein synthesis allowing an immediate response to environmental cues or cellular states.
Biological function summary
IER2 influences cell proliferation and differentiation. It interacts with several signaling pathways indicating its role in controlling cell cycle progression. Scientists have discussed IER2's involvement in cellular stress responses acting independently rather than as part of a larger protein complex. These activities help the protein regulate gene expression temporarily an important element in maintaining cellular homeostasis.
Pathways
IER2 functions within signaling networks essential for mitogenic responses and stress-activated MAPK pathways. It shares pathways with proteins such as c-Fos and c-Jun which are part of the AP-1 transcription factor complex. These connections position IER2 as a participant in pathways that manage cellular responses to external stimuli and internal signals important for cell growth and survival.
Scientists associate IER2 with cancer and neurodegenerative conditions. In cancer IER2 promotes metastasis by influencing cell migration and invasion often through interaction with matrix metalloproteinases. Additionally its dysregulation may contribute to neurodegenerative disorders linking it to proteins involved in neuronal survival and death. Understanding these interactions could provide insight into therapeutic targets for combatting related diseases.
